Alpha Cognition Inc (ACOG)

Alpha Cognition announced the pricing of an upsized public offering of common shares and received approval to list its common shares on the Nasdaq Capital Market in November 2024. In October 2025, the company announced a proposed underwritten public offering of common shares and pre-funded warrants. The company reported its third-quarter 2025 financial results in November 2025, highlighting ZUNVEYL launch momentum with approximately $2.8 million in total revenue for the quarter. In March 2026, Alpha Cognition reported fourth-quarter 2025 net product revenue of $2.5 million for ZUNVEYL, contributing to a full-year 2025 total revenue of $10.2 million and also announced the execution of a second national PBM contract. ACOG's stock has seen a 52-week high of $11.54 and a low of $3.75. As of March 20, 2026, the share price was $5.71.

The provided information does not explicitly detail demand seasonality for Alpha Cognition, Inc.'s products and services. However, recent financial reports indicate growing demand for ZUNVEYL, with fourth-quarter 2025 bottles dispensed increasing by 62% quarter-over-quarter, and December being the strongest month since launch. The company also noted increasing rates of repeat ordering, suggesting consistent demand rather than strong seasonal fluctuations.

Alpha Cognition, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for neurodegenerative diseases, including Alzheimer's disease and ALS. The company operates within the Health Care sector, specifically in the Biotechnology and Pharmaceuticals & Biotech industries. Its major products and pipeline candidates include ZUNVEYL (benzgalantamine), an oral tablet formulation approved for the treatment of mild-to-moderate Alzheimer's disease and also being developed for cognitive impairment with mild traumatic brain injury (mTBI). ALPHA-1062 is being developed in combination with memantine for moderate-to-severe Alzheimer's dementia, and as an intranasal formulation for cognitive impairment with mTBI. ALPHA-0602 is a gene therapy in development for the treatment of ALS. ALPHA-0702 and ALPHA-0802 are granulin epithelin motifs being developed for the treatment of neurodegenerative diseases.

Alpha Cognition Inc. is headquartered in Vancouver, British Columbia, Canada, and Grapevine, Texas, USA. The company's operations and commercialization efforts for ZUNVEYL are primarily focused on the United States and Canada.

Information directly detailing Alpha Cognition Inc.'s brand reputation in the past year is not explicitly available. However, the company's financial reports and business updates indicate a focus on the commercial launch and adoption of ZUNVEYL for Alzheimer's disease. Positive clinician feedback on ZUNVEYL's impact on cognitive function, behavioral symptoms, and safety profile, along with strong growth in pharmacy orders and an expanding prescriber base, suggest a developing positive reputation for its lead product within the long-term care market.

Alpha Cognition Inc. has 29 institutional owners and shareholders who have filed 13D/G or 13F forms with the SEC, holding a total of 9,909,100 shares. Hedge funds own 20% of Alpha Cognition, with Opaleye Management Inc. being the largest shareholder, holding 9.0% of outstanding shares. Retail investors hold the largest share of the company, with 50% ownership.